- Home
- ONON vs RPRX Comparison
ONON vs RPRX Comparison
Compare ONON & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONON
- RPRX
- Stock Information
- Founded
- ONON 2010
- RPRX 1996
- Country
- ONON Switzerland
- RPRX United States
- Employees
- ONON N/A
- RPRX N/A
- Industry
- ONON Shoe Manufacturing
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONON Consumer Discretionary
- RPRX Health Care
- Exchange
- ONON Nasdaq
- RPRX Nasdaq
- Market Cap
- ONON 14.8B
- RPRX 15.6B
- IPO Year
- ONON 2021
- RPRX 2020
- Fundamental
- Price
- ONON $41.58
- RPRX $36.33
- Analyst Decision
- ONON Strong Buy
- RPRX Strong Buy
- Analyst Count
- ONON 19
- RPRX 4
- Target Price
- ONON $63.95
- RPRX $44.50
- AVG Volume (30 Days)
- ONON 5.3M
- RPRX 4.4M
- Earning Date
- ONON 11-11-2025
- RPRX 11-05-2025
- Dividend Yield
- ONON N/A
- RPRX 2.43%
- EPS Growth
- ONON N/A
- RPRX 54.86
- EPS
- ONON 0.52
- RPRX 2.32
- Revenue
- ONON $3,417,915,703.00
- RPRX $2,305,243,000.00
- Revenue This Year
- ONON $30.44
- RPRX $35.14
- Revenue Next Year
- ONON $23.91
- RPRX $1.24
- P/E Ratio
- ONON $80.39
- RPRX $15.55
- Revenue Growth
- ONON 35.67
- RPRX 3.02
- 52 Week Low
- ONON $34.59
- RPRX $24.05
- 52 Week High
- ONON $64.05
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- ONON 42.71
- RPRX 54.35
- Support Level
- ONON $41.41
- RPRX $35.23
- Resistance Level
- ONON $43.02
- RPRX $36.36
- Average True Range (ATR)
- ONON 1.43
- RPRX 0.59
- MACD
- ONON -0.01
- RPRX 0.05
- Stochastic Oscillator
- ONON 25.00
- RPRX 81.64
About ONON On Holding AG
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.